Navigation Links
Researchers find relief for chronic pain
Date:1/22/2008

Researchers in the Department of Medicine and Department of Neurosciences at Mount Sinai School of Medicine have discovered that chronic pain can be successfully treated with novel targeted gene therapy. In an effort to find a more effective treatment for chronic pain, researchers at Mount Sinai developed a gene therapy technique that simulates the pain-killing effect of opiate drugs. In the new study Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain published in the January 22, 2008 issue of the Proceedings of the National Academy of Sciences (PNAS), researchers suggest that gene therapy for pain might in the future become a treatment alternative for patients with severe chronic pain.

Fifty million Americans suffer from chronic pain. Chronic pain patients often do not experience satisfactory pain relief from available treatments due to poor efficacy or intolerable side effects like extreme sleepiness, mental clouding, and hallucinations, said Dr. Andreas Beutler, MD, principal investigator of the study and Assistant Professor of Medicine/ Hematology And Medical Oncology at Mount Sinai School of Medicine.

Mount Sinai researchers designed a viral vector to carry the prepro-b-endorphin gene into primary sensory neurons in order to activate opiate receptors selectively, in a rat model. The agents were delivered directly into the spinal fluid of rats via a lumbar puncture, or spinal tap with only one injection. Results showed that the rats remained symptom-free for an extended period of time.

Our research found that treating chronic pain with Adeno-Associated Virus vector-based gene therapy allows for pain relief for more than three months after a single injection, targeting selectively the pain gate. The technique worked successfully with opioid- and non-opioid therapeutic genes, said Dr. Beutler. Targeted gene therapy will likely avoid the unwanted side effects associated with opioid painkillers such as morphine. Based on our findings, this targeted gene therapy via lumbar puncture appears to be a promising candidate for bench-to-bedside research that might ultimately be tested in patients with intractable chronic pain, e.g., to help patients suffering from severe pain due to advanced cancer.


'/>"/>

Contact: Mount Sinai Newsroom
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers propose consumers buy yearly drug licenses as new way to pay for prescriptions
2. Pros, cons of drug proven to prevent prostate cancer should be considered, researchers recommend
3. DOE awards supercomputing time to UCSD, SDSC researchers
4. Argonnes Blue Gene/P to host large cadre of INCITE researchers
5. Researchers Hone in on Cancer Stem Cells for Melanoma
6. Anyone can save a life: Penn researchers lead national efforts to improve CPR quality
7. Researchers find new way to block destructive rush of immune cells
8. U of M researchers create beating heart in laboratory
9. Researchers challenge previous findings regarding widely used asthma treatment
10. UT Health Science Center researchers decoding saliva to detect breast cancer
11. Protein power: Researchers trigger insulin production in diabetic mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims ... employees that are both engaging and easy to use. Coming off the heels ... company revealed today its plans to roll out new AI-powered self-service enhancements to ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to ... convenient service for Texas, they are expanding their presence in Dallas. One of the ... that will bring new jobs to the Dallas and Forth Worth market. STAT takes ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital health ... led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and ... to serve more consumers who are managing chronic conditions or simply want ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/8/2016)... ... 2016 , ... Bill Mull Agencies, a Wichita-based firm offering ... central Kansas, is joining the Youth Horizons organization for a charity event that ... Wichita, Youth Horizons works to empower area children from unstable, troubled, or single-parent ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: